Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease

被引：11
|
作者：
Moghavem, Nuriel [1 ]
Henderson, Victor W. [2 ,3 ]
Greicius, Michael D. [4 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90007 USA
[2] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷 / 03期
关键词：
POSITRON-EMISSION-TOMOGRAPHY;
D O I：
10.1002/ana.26167
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：331 / 333
页数：3
相关论文
共 50 条
  • [31] The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
    Jeff Sevigny
    Ping Chiao
    Thierry Bussière
    Paul H. Weinreb
    Leslie Williams
    Marcel Maier
    Robert Dunstan
    Stephen Salloway
    Tianle Chen
    Yan Ling
    John O’Gorman
    Fang Qian
    Mahin Arastu
    Mingwei Li
    Sowmya Chollate
    Melanie S. Brennan
    Omar Quintero-Monzon
    Robert H. Scannevin
    H. Moore Arnold
    Thomas Engber
    Kenneth Rhodes
    James Ferrero
    Yaming Hang
    Alvydas Mikulskis
    Jan Grimm
    Christoph Hock
    Roger M. Nitsch
    Alfred Sandrock
    Nature, 2016, 537 : 50 - 56
  • [32] Aducanumab-Hope or Disappointment for Alzheimer's Disease
    Wojtunik-Kulesza, Karolina
    Rudkowska, Monika
    Orzel-Sajdlowska, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [33] The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
    Sevigny, Jeff
    Chiao, Ping
    Bussiere, Thierry
    Weinreb, Paul H.
    Williams, Leslie
    Maier, Marcel
    Dunstan, Robert
    Salloway, Stephen
    Chen, Tianle
    Ling, Yan
    O'Gorman, John
    Qian, Fang
    Arastu, Mahin
    Li, Mingwei
    Chollate, Sowmya
    Brennan, Melanie S.
    Quintero-Monzon, Omar
    Scannevin, Robert H.
    Arnold, H. Moore
    Engber, Thomas
    Rhodes, Kenneth
    Ferrero, James
    Hang, Yaming
    Mikulskis, Alvydas
    Grimm, Jan
    Hock, Christoph
    Nitsch, Roger M.
    Sandrock, Alfred
    NATURE, 2016, 537 (7618) : 50 - 56
  • [34] New drugs for Alzheimer's disease: Aducanumab or Donanemab?
    Joodaki, Mehran
    Shirazi, Mona Merati
    Hosseini, Nasrin
    PHYSIOLOGY AND PHARMACOLOGY, 2024, 28 (03): : 219 - 236
  • [35] Population Pharmacokinetics of Aducanumab in Patients with Alzheimer's Disease
    Kandadi, Kumar
    Nestorov, Ivan
    von Rosenstiel, Philipp
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S68 - S68
  • [36] Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability
    Thussu, Shreeya
    Naidu, Aniketh
    Manivannan, Sindhu
    Grossberg, George T.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1045 - 1053
  • [37] Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease
    Abyadeh, Morteza
    Gupta, Vivek
    Gupta, Veer
    Chitranshi, Nitin
    Wu, Yunqi
    Amirkhani, Ardeshir
    Meyfour, Anna
    Sheriff, Samran
    Shen, Ting
    Dhiman, Kunal
    Salekdeh, Ghasem H.
    Haynes, Paul A.
    Graham, Stuart L.
    Mirzaei, Mehdi
    AGING AND DISEASE, 2021, 12 (08): : 1964 - 1976
  • [38] Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials
    Cummings, J.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2022, 9 (02): : 241 - 246
  • [39] Public Policy Should Foster Alzheimer’s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials
    J. Cummings
    The Journal of Prevention of Alzheimer's Disease, 2022, 9 : 241 - 246
  • [40] Aducanumab for Alzheimer's disease: expediting approval and delaying science
    Salinas, Rodrigo A.
    BMJ EVIDENCE-BASED MEDICINE, 2021, 26 (05) : 214 - 215
12345